Table 2. High lightened studies of targeted treatment and possible biomarkers of malignant pleural mesothelioma.

First name, year, ref	Phase/ study	n	Chemotherapy regimens	Targeted treatment/biomarker investigated	Response rates (RR)	Median progression-free survival (PFS) months	Median overall survival (OS) months	Outcome
Gregorc, 2010 (81)	II	57	Pemetrexed	Human tumor necrosis factor alpha	44-46%	2.8	12.1	Warrant additional evaluation
Kindler, 2012 (80)	II	108	Gemcitabine/Cisplatin	Bevacizumab	24.5%	6.9	15.6	Addition of bevacizumab did not significantly improve PFS or OS
Nowak, 2013 (82)	II	30	Pemetrexed/Platinum	Vascular Disrupting Agent BNC105P	43%	1.5	8.2	Insufficient
O’Brien, 2013 (83)	II	82	Cisplatin and bortezomib	-	28.4%	5.1	13.5	PFS rate at 18 weeks as strong predictor of survival